[Pharmacological treatment of Rett syndrome improves breathing and survival in a mouse model]

Med Sci (Paris). 2007 Oct;23(10):805-7. doi: 10.1051/medsci/20072310805.
[Article in French]
No abstract available

Publication types

  • News

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology
  • Adrenergic Uptake Inhibitors / therapeutic use*
  • Animals
  • Brain Stem / pathology
  • Brain Stem / physiopathology
  • Cells, Cultured / drug effects
  • Cells, Cultured / metabolism
  • Desipramine / pharmacology
  • Desipramine / therapeutic use*
  • Drug Evaluation, Preclinical
  • Female
  • Humans
  • Methyl-CpG-Binding Protein 2 / deficiency
  • Methyl-CpG-Binding Protein 2 / genetics
  • Methyl-CpG-Binding Protein 2 / physiology
  • Mice
  • Mice, Knockout
  • Nerve Tissue Proteins / deficiency
  • Neurons / enzymology
  • Neurons / pathology
  • Norepinephrine / deficiency
  • Norepinephrine / physiology
  • Respiration Disorders / drug therapy*
  • Respiration Disorders / etiology
  • Rett Syndrome / complications
  • Rett Syndrome / drug therapy*
  • Rett Syndrome / genetics
  • Rett Syndrome / physiopathology
  • Synaptic Vesicles / drug effects
  • Synaptic Vesicles / metabolism
  • Tyrosine 3-Monooxygenase / deficiency

Substances

  • Adrenergic Uptake Inhibitors
  • MECP2 protein, human
  • Mecp2 protein, mouse
  • Methyl-CpG-Binding Protein 2
  • Nerve Tissue Proteins
  • Tyrosine 3-Monooxygenase
  • Desipramine
  • Norepinephrine